Cyclo Therapeutics (CYTH)
(Delayed Data from NSDQ)
$0.66 USD
-0.02 (-3.06%)
Updated Sep 10, 2024 03:59 PM ET
After-Market: $0.66 0.00 (0.00%) 7:58 PM ET
4-Sell of 5 4
F Value B Growth A Momentum D VGM
Industry / Sector Report
Industry : Medical - Biomedical and Genetics
Zacks Industry Rank
Top 33% (83 out of 250)Zacks Sector Rank
Top 25% (4 out of 16)Recommendations and Estimates
Company | Industry | SP500 | |
---|---|---|---|
Average Recommendation (1=Buy, 5=Sell) | 2.67 | 1.37 | 9.99 |
Current Quarter Estimate | -0.15 | 2.89 | 61.00 |
Year Ago Quarter Estimate | -0.29 | -4.83 | 54.84 |
Next Quarter Estimate | -0.17 | 3.94 | 63.00 |
Next Year Estimate | -0.66 | 25.11 | 275.00 |
Growth Rates
Company | Industry | SP500 | |
---|---|---|---|
This Year | 46.34 | 17.60 | 15.67 |
Next Year | 0.00 | 9.60 | 11.34 |
Last 5 Years | NA | 0.90 | 8.10 |
Next 5 Years | NA | 21.70 | NA |
Financials
Company | Industry | |
---|---|---|
Price/Earnings (TTM) | NA | -7.39 |
Price/Book (MRQ) | NA | 1.97 |
Price/Cash Flow (MRFY) | NA | 16.43 |
Dividend Yield | 0.00% | 0.00% |
Net Profit Margin (TTM) | -1,830.27% | -152.35% |
Return on Equity (TTM) | -2,741.89% | -60.91% |
Debt to Equity (MRQ) | 0.00 | 0.00 |
MRQ = Most Recent Quarter
TTM = Trailing Twelve Months
MRFY = Most Recent Fiscal Year
Note: Company and S&P 500 ratios relating to share price calculated daily; all others calculated weekly or in accordance with company earnings announcement. Industry medians calculated weekly.